Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Eli Lilly

What Does the Future Hold for Eli Lilly?

Eli Lilly's two major GLP-1 drugs have dominated headlines, but a slate of new treatments in development—and some already available—suggest a bright future.

MarketBeat

Why isn’t Ozempic on Australia’s Pharmaceutical Benefits Scheme for weight loss? And should it be?

The drug is subsidised for treatment of type 2 diabetes but experts say it could help reduce other health problems associated with severe obesity

The Guardian - AU

Ultrasound Weight Loss: GE HealthCare and Novo Nordisk’s Play

GLP-1 drugs have been all the rage for weight loss, but GE Healthcare and Novo Nordisk are working on a non-invasive approach to controlling metabolic functions

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

How we diagnose and define obesity is set to change – here’s why, and what it means for treatment

Obesity is linked to many common diseases, such as type 2 diabetes, heart disease, fatty liver disease and knee osteoarthritis.

The Conversation

Stock Market Today: Stocks Are Mixed Ahead of CPI

Cool wholesale inflation numbers provide only slight relief before Wednesday's release of December Consumer Price Index data.

Kiplinger

Eli Lilly: 4 Reasons Investors Shouldn’t Miss This Opportunity

Eli Lilly shares are down 17.7% from its highs. The company posted 128% YoY revenue jump in its Mounjaro GLP-1/GIP treatment with no signs of slowing down.

MarketBeat

Trump Wants Greenland. Why That Could Be Bad News for Novo Nordisk Stock.

The pharma giant’s stock has been under pressure since the Greenland issue has been in the spotlight.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Eli Lilly's Q4 2024 Earnings: What to Expect

Eli Lilly is scheduled to release its Q4 earnings report next month, and analysts forecast triple-digit profit growth.

Barchart

Arianna Huffington's Thrive Global partners with Eli Lilly

Patients can watch a video on how to de-stress in the same place they fill their prescriptions.

Fortune

Elon Musk Weighs In on Weight-Loss Drug Stocks. Is LLY or NVO a Better Buy?

Elon Musk’s preference for Eli Lilly’s Mounjaro over Novo Nordisk’s Ozempic has sparked increased interest in weight-loss drug stocks.

Barchart

Is Eli Lilly Stock a Buy, Sell, or Hold for 2025?

Eli Lilly is very close to joining the $1 trillion club. Should you buy shares now?

Barchart

All-Pro safety Brian Dawkins NFL’s defensive adjustments amid rule changes

All-Pro safety Brian Dawkins comments on how NFL defenses have adjusting to the league's changing rules w/ @EdEastonJr

USA Today Sports Media Group

3 Big-Name Stocks Just Announced Big-Time Dividend Increases

Eli Lilly, plus two other massive companies, just announced double-digit percentage increases in their quarterly dividend payments.

MarketBeat

Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon

Novo Nordisk A/S is moving closer to adding more sales for its blockbuster GLP-1 drug semaglutide to treat a chronic liver disease.

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

3 Healthcare Stocks to Buy Now for a Healthy Portfolio in 2025

The healthcare industry is set for growth due to the growing demand for quality treatments and ongoing progress in medical technology. Hence, investors might consider investing in healthcare stocks, Eli Lilly (LLY), Thermo Fisher Scientific (TMO), and Abbott Laboratories (ABT) for a healthy portfolio in 2025. Read more….

International Business Times

Eli Lilly To Invest $3B To Expand Plant To Meet Surge In Demand For Weight Loss Drugs

Construction on the facility in Kenosha County, Wis., is expected to begin next year.

Top News

President-Elect Trump Hosts Pharmaceutical Ceos For Dinner At Mar-A-Lago

President-elect Trump's dinner with pharmaceutical executives and healthcare appointees highlights industry collaboration and healthcare challenges.

MarketBeat

2 Telehealth Stocks That Could Gain from Trump’s New FDA Pick

Discover two telehealth stocks, Hims & Hers (HIMS) and Teladoc (TDOC), poised to benefit from Trump's FDA nominee, Dr. Marty Makary, a telemedicine advocate.

The Independent UK

Obese people ‘will have to wait’ for weight loss jab Mounjaro, NHS officials warn

Mounjaro to be rolled out to only patients with the highest needs, the NHS has said

The Independent UK

Obese people ‘will have to wait’ for Mounjaro amid carefully managed NHS rollout

The decision will help ‘protect other vital NHS services’.

The Independent UK

Weight-loss meds go head-to-head in new study. One was significantly more effective, drugmaker says

In the first head-to-head test, people using Eli Lilly’s Zepbound lost just over 50 pounds while those using competitor Novo Nordisk’s Wegovy shed more than 33 pounds

Benzinga

Stock Of The Day: Where Will The Eli Lilly Rally End?

Shares of Eli Lilly (LLY) are approaching a price level that had previously been a peak. There is a good chance they hit resistance at it.

Benzinga

Decoding Eli Lilly's Options Activity: What's the Big Picture?

Investors with a lot of money to spend have taken a bearish stance on Eli Lilly (NYSE:LLY).

1 … 15 16 17 18

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.